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a b s t r a c t
Human papillomavirus type 16 (HPV16) is a major cause of cervical cancer. We previously demonstrated
that C-to-T and G-to-A hypermutations accumulated in the HPV16 genome by APOBEC3 expression
in vitro. To investigate in vivo characteristics of hypermutation, differential DNA denaturation-PCR (3D-
PCR) was performed using three clinical specimens obtained from HPV16-positive cervical dysplasia, and
detected hypermutation from two out of three specimens. One sample accumulating hypermutations in
both E2 and the long control region (LCR) was further subjected to Next-Generation Sequencing,
revealing that hypermutations spread across the LCR and all early genes. Notably, hypermutation was
more frequently observed in the LCR, which contains a viral replication origin and the early promoter.
APOBEC3 expressed abundantly in an HPV16-positive cervix, suggesting that single-stranded DNA
exposed during viral replication and transcription may be efﬁcient targets for deamination. The results
further strengthen a role of APOBEC3 in introducing HPV16 hypermutation in vivo.
& 2015 Elsevier Inc. All rights reserved.
Introduction
Human papillomavirus type 16 (HPV16) is a nonenveloped DNA
virus and a causative agent of cervical and oropharyngeal cancers
(Bodily and Laimins, 2011; Kreimer and Chaturvedi, 2011; Stanley
et al., 2007; zur Hausen, 2002). HPV16 has a 7.9-kb closed circular
genomic DNA that contains at least eight open reading frames (E1,
E2, E4, E5, E6, E7, L1, and L2) and a noncoding, long control region
(LCR). The LCR contains the replication origin and the early
promoter responsible for the transcription of the E6 and E7 genes,
which are viral oncogenes required for cellular transformation
(Bodily and Laimins, 2011; Stanley et al., 2007; zur Hausen, 2002).
HPV16 establishes its genome as extrachromosomal episomes in
infected epithelial cells. HPV16 infection induces hyperplasia of
epithelial cells, thereby disturbing the normal histological architec-
ture of the cervical epithelium, which clinically manifests as cervical
intraepithelial neoplasia (CIN) grades 1, 2, and 3 (Vinay et al., 2007).
In invasive cervical cancer, HPV DNA is frequently found integrated
into the host genome, leading to constitutive expression of E6 and
E7. Because E2 encodes a viral transcriptional repressor of the early
promoter responsible for E6/E7 expression, the disruption of the E2
gene by viral integration may favor the progression into cervical
cancer (Stanley et al., 2007). However, the mechanisms underlying
viral DNA integration, in particular, which factors initiate DNA
strand breaks, have not been clariﬁed.
APOBEC proteins are a family of enzymes that convert cytosine
into uracil in DNA and RNA. In humans, the APOBEC family is
composed of 11 members, including AID and APOBEC1, 2, 3A, 3B,
3C, 3DE, 3F, 3G, 3H, and 4 (Goila-Gaur and Strebel, 2008; Harris and
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Liddament, 2004; Malim, 2009; Vieira and Soares, 2013). AID
(Muramatsu et al., 2000) is known to trigger somatic hypermuta-
tion, class switch recombination, and gene conversion in immuno-
globulin genes (Ganesh and Neuberger, 2011; Zan and Casali, 2013).
APOBEC3(A3)s are counteracting factors against viruses such as
HIV-1 and transposable elements (Goila-Gaur and Strebel, 2008;
Harris and Liddament, 2004; Malim, 2009; Vieira and Soares, 2013).
In the case of HIV-1, APOBEC3G(A3G) inhibits viral reverse tran-
scription in infected cells and introduces a C-to-T hypermutation in
viral nascent DNA, which leads to the inhibition of HIV-1 replication
by base excision repair (BER)-mediated DNA cleavage or the
accumulation of destructive mutations in the viral genome (Goila-
Gaur and Strebel, 2008; Harris and Liddament, 2004; Malim, 2009;
Vieira and Soares, 2013). Recently, APOBEC proteins have been
proposed to be involved in carcinogenesis. It has been suggested
that APOBEC3A(A3A) and 3B(A3B) contribute to mutation load in
multiple human tumors including bladder, cervical, lung, head and
neck, and breast cancers (Burns et al., 2013; Roberts et al., 2013).
However, the involvement of APOBEC proteins in the pathophysiol-
ogy of HPV-related diseases is largely unknown.
Previous studies suggested the presence of hypermutation in the
E2 gene and the LCR of HPV16 by differential DNA denaturation PCR
(3D-PCR), a highly sensitive method used to detect hypermutated DNA
by preferentially amplifying AT-rich DNA at lower denaturation
temperature (Kukimoto et al., 2015; Vartanian et al., 2008; Wang et
al., 2014). However, little is known about its frequency in the total viral
population in patients infected with HPV16 and whether such
hypermutation occurs in other regions of the HPV16 genome. Thus,
we performed in-depth investigation of HPV16 hypermutation in CIN1
lesions using two methods: 3D-PCR and Next-Generation Sequencing
(NGS), a non-biased method to determine sequence variations.
Results
Expression of APOBEC3s in healthy and HPV16-positive cervical
specimens
We previously reported that A3s are abundantly expressed and
mRNA levels of A3A, A3F, and A3G were increased by treatment
with interferon (IFN)-β in an in vitro model of HPV16-positive
cervical keratinocytes, W12 (Wang et al., 2014). To further examine
A3 expression in vivo, total RNA from healthy and HPV16-positive
cervical specimens were subjected to RT-qPCR analysis. The level of
A3 and HPV16 E6/E7 expression was examined in these specimens.
The HPV16-positive cell line CaSki was also included as a control.
We found that A3s are abundantly expressed in both HPV16-
positive and -negative cervix tissues (Fig. 1A). Previous studies
reported that A3B expression was upregulated by HBV16 E6/E7
(Mori et al., 2015; Ohba et al., 2014; Vieira et al., 2014). However, the
HPV16-positive specimen used in this study expressed low levels of
A3B (Fig. 1B). As shown in Fig. 1C, HPV16 E6/E7 expression was
lower in the HPV16-positive specimen than in CaSki cells. We
speculate that low levels of A3B expression in the HPV16-positive
specimen could be attributed to low levels of E6/E7 expression.
Hypermutation in HPV16-E2 and LCR detected by 3D-PCR
To detect hypermutation in our clinical samples, 3D-PCR was
employed as previously reported (Vartanian et al., 2008; Wang
et al., 2014). Total DNA extracted from cervical exfoliated cells of
patients with HPV16-positive lesions was subjected to 3D-PCR. E2
3D-PCR ampliﬁed control DNAs containing 0, 4, and 27 C-to-T
mutations at denaturation temperatures of 86.0 1C, 85.6 1C, and
83.8 1C, respectively (Fig. 2A). This indicates that our E2 3D-PCR can
detect hypermutated E2 DNA differentially according to the
hypermutation load per target DNA. As shown in Fig. 2A, two
(85.1 1C for #1291 and 83.8 1C for #1300) of three CIN1 samples
(#1291, #1300, and #1605) show ampliﬁcation of E2 DNA at lower
denaturation temperatures than that used for 4 p.c., suggesting the
presence of hypermutated E2 DNA. It is of note that the samples in
which hypermutated E2 gene was detected were collected a longer
time after the initial diagnosis of CIN1 (#1291, 13.5 months; #1300,
15.5 months), compared to #1605 in which E2 gene was not
hypermutated (#1605, 1.5 months). Sequencing the PCR amplicons
obtained at the denaturation temperature lower than that used for the
negative control (n.c.), revealed the obvious accumulation of C-to-T
and G-to-A mutations (Fig. 2B). The average number of C-to-T and G-
to-A mutations per clone was 4.9 for sample #1291 and 13.0 for
#1300, which is within the range of the mutation load expected from
the control 3D-PCR reaction. Identiﬁed mutations were heavily biased
to either C-to-T or G-to-A mutations (Fig. S2), consistent with the
previous ﬁnding of an A3-inducing E2 hypermutation in vitro (Wang
et al., 2014). A 50-dinucleotide context analysis of mutations revealed a
preference for TpC and CpC over ApC and GpC dinucleotides (Fig. 2C)
for sample #1300, whereas a preference for the GpC dinucleotide was
obvious in sample #1291.
RCA can robustly amplify closed circular DNA (Chowdhury et al.,
2013; Kitamura et al., 2013). RCA analysis revealed the presence of the
episomal viral DNA in #1300, but not #1291 (Fig. S3A). The following
E2 3D-PCR detected hypermutated viral DNA in #1300 (Fig. 1A). The
sequences of these products exhibited a preference for TpC dinucleo-
tides, as exhibited in the total DNA of #1300 (Fig. S3B–D).
Fig. 1. A3s are abundantly expressed in HPV16-negative and -positive cervical
specimens. Total RNAs from HPV16-negative and -positive cervical specimens and
CaSki cells were subjected to RT-qPCR analysis to quantify mRNA levels of A3s (A),
A3B (B), and HPV16 E6 and E7 (C). Each copy number of A3 was normalized by that
of HPRT.
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Because the HPV16 LCR is another target of A3-dependent
hypermutations (Vartanian et al., 2008; Wang et al., 2014), 3D-PCR
was also performed for the LCR. As shown in Fig. S4A, total DNA
from sample #1300 showed ampliﬁcation at as low as 77.7 1C,
whereas that from #1291 showed ampliﬁcation at 79.9 1C or higher,
comparable to the n.c. Robust C-to-T/G-to-A hypermutations were
conﬁrmed by sequencing the PCR products that were ampliﬁed at a
lower denaturation temperature than that used for the n.c. (Fig. S4B,
21.3 per clone, and Fig. S5). Its dinucleotide preference was biased
toward TpC and CpC (Fig. S4C). The considerably stronger TpC
preference observed in the LCR and E2 hypermutation in sample
#1300 suggests the contribution of A3s (Henry et al., 2009; Hultquist
et al., 2011; Stenglein et al., 2010; Vartanian et al., 2008).
Hypermutation of HPV16 early genes revealed by NGS analysis
Further to estimate the distribution of hypermutation as well as
the frequency of hypermutations in the clinical samples, the LCR and
the early gene region of HPV16 (nt7582-nt3944, AF125673.1) in
sample #1300 were ampliﬁed by conventional PCR, and the ampli-
cons were subjected to NGS. An HPV16 plasmid (p1203) was
sequenced in parallel with sample #1300 to assess the frequency
of mutations inherent to any NGS procedures, including PCR, library
construction, and data analyses (Fig. S1). We obtained 1,492,486 and
1,054,876 reads, whose sequences were mapped to HPV16 con-
ﬁrmed by paired-end reads, for the plasmid control and sample
#1300, respectively (Fig. 3A and B). Meanwhile, although sample
#1300 contained co-infected HPV56 as much as HPV16, the number
of reads mapped to HPV56 was only 120 for #1300 (data not
shown). Mutations were identiﬁed by comparing each reads with
the consensus sequence reassembled from read sequences of #1300
and the plasmid control (deposited in DDBJ, accession no. LC027223
and LC027929, respectively). The reads were sorted according to the
number of C-to-T/G-to-A mutations per read (Fig. 3A and B). Notably,
the number of reads in the plasmid control dropped exponentially
according to the number of mutations in a read, consistent with the
independent events of mutation, while the number of reads in
sample #1300 did not drastically decrease and reads with 3 muta-
tions or more per read were detected, suggesting the concurrent
mechanism of multiple mutations (Fig. 3A). Thus most of the reads
with 3 or more mutations are considered to have undergone a
hypermutation event. As summarized in Fig. 3B, #1300 contained
212 reads with three or more C-to-T/G-to-A mutations, whereas the
plasmid control had just a single read with three C-to-T/G-to-A
mutations and none with more. Thus, the frequency of C-to-T/G-to-A
hypermutations is estimated to be 0.020% (¼212/1,054,876). This
frequency may underestimate real hypermutation events in vivo
because the present study does not count one and two C-to-T/G-to-
A mutations per read as a hypermutation event. Examples of read
sequences with robust hypermutation are shown in Fig. S6. Con-
secutive 17 C-to-T mutations were found in the minus strand of the
viral DNA from the E1 and E7 genes. Such consecutive C-to-T
mutations in one strand are a typical characteristic of the A3-
mediated hypermutation (Roberts and Gordenin, 2014). As shown
in Fig. 3C, the mutations were obviously biased to either the G-to-A
or C-to-T conversion, and TpC/GpA dinucleotide preferences were
also prominent (Fig. 3D), which is consistent with the proposed
signature of A3-mediated hypermutation (Henry et al., 2009;
Stenglein et al., 2010).
Intriguingly, hypermutated reads (in particular, G-to-A) were
distributed not only to the LCR and E2 gene but also to the region
between them (Fig. 4E). TpC/GpA dinucleotide frequency seems to
correlate with distribution of the G-to-A hypermutated read, parti-
cularly in the region from middle of the E1 to E5 genes (compare
Fig. 4B with Fig. 4E). Collectively, these molecular characteristics of
G-to-A/C-to-T hypermutations (polarity of strand, consecutive muta-
tion, and dinucleotide preference) further strengthen a role of
APOBEC3 proteins in introducing HPV16 hypermutation in vivo.
Discussion
In this study, we demonstrated C-to-T/G-to-A hypermutations in
the HPV16 genome in CIN1 specimens by both 3D-PCR and NGS. Of
note, the NGS analyses revealed two interesting characteristics of
hypermutation in the HPV16 genome in vivo. First, reads containing
C-to-T/G-to-A hypermutations appeared to be concentrated on the
LCR which contains a viral replication origin and the p97 early
promoter (Fig. 4D and E). The replication origin and p97 promoter
may have more chances to be exposed as a single-stranded DNA than
Fig. 2. 3D-PCR analysis of the HPV16 E2 gene. Total DNA was isolated from cervical
exfoliated cells collected from three patients with HPV16-positive CIN1 lesions.
Twenty-ﬁve nanograms of the extracted DNA as well as the RCA products from
#1300 were subjected to 3D-PCR targeting HPV16 E2 (A). Plasmids containing
fragments of the E2 gene carrying the indicated number of C-to-T mutations were
used simultaneously as control reactions (e.g., n.c. indicates no mutations, whereas
4 and 27 p.c. indicate 4 and 27 C-to-T mutations, respectively). Total DNA from
samples #1291, #1300, and the RCA product from #1300 showed ampliﬁcation at
denaturation temperatures lower than that of the n.c. (86.0 1C). For RCA, see also
Fig. S3. (B and C) E2 3D-PCR products ampliﬁed using lower denaturation
temperatures compared with the n.c. (indicated by a vertical dotted line) were
puriﬁed, cloned into a T vector, and sequenced. The sequenced clone number and
overall nucleotide number are indicated below each of the matrices. The mutations
identiﬁed are shown as mutation matrices (B) and the result of the 50-dinucleotide
context analysis is shown in (C) (*Po0.05 and ***Po0.005). For (B), the reference
sequence (GenBank accession number: AF125673.1) was used to identify
mutations.
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other viral genome regions. It is likely that A3s, single-stranded DNA
deaminases, may target the LCR and introduce hypermutation in the
LCR. Second, the NGS analyses also revealed hypermutation frequency
in the total viral population as rarely as an order of 104, which is
incomparably lower than the estimated mutation frequency of
4102 by A3s in the HIV-1 genome (Knoepfel et al., 2011; Zhang
et al., 2003). It is thus unlikely that HPV16 hypermutation suppresses
the viral replication efﬁciently as for HIV-1, which is in agreement
Fig. 3. NGS analysis of hypermutated HPV16 genomes in vivo. (A, B) The read sequences obtained from the LCR-E5 region of HPV16 genomes were aligned to the consensus
sequences (DDBJ, accession no. LC027223 for #1300 and LC027929 for the plasmid control), and sorted according to the number of C-to-T/G-to-A mutations per read. The
frequency of reads, with the indicated number of mutations per read, is shown in (A). The blue and the magenta circles indicate the control plasmid and #1300, respectively.
The clinical specimen #1300 yielded 212 reads with 3 or more C-to-T/G-to-A mutations, while the plasmid control yielded only a single read (B, ***Po0.005). (C, D) Mutation
matrices (C) and the 50-dinucleotide context analysis (D) of the reads that contain 3 or more C-to-T/G-to-A mutations (***Po0.005).
Fig. 4. Reads containing three or more C-to-T/G-to-A mutations in #1300 were mapped. (A) The coverage and the depth of the total output reads. (B) The frequency of the
TpC and GpA dinucleotide contexts per 100-bp of the consensus sequence. (C) The frequency of reads containing three or more C-to-T/G-to-A mutations. (D, E) The reads
containing three or more C-to-T (D) or G-to-A (E) mutations, mapped to the #1300 consensus sequence (LC027223) and visualized by Integrative Genomics Viewer. Magenta,
green, blue, and orange tics represent the bases substituted by T, A, C, and G, respectively. For reference, LCR, the early and late promoters (p97 and p670), position of 3D-PCR
targets (double arrows), and the early genes (E6, E7, E1, E2, E4, E5) in the consensus sequence are indicated on the top.
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with our previous observations that A3 overexpression leads to E2
hypermutation but does not suppress HPV16 replication in W12 cells
(Wang et al., 2014). We speculate that A3s may not have an effective
mechanism to target the HPV16 genome, whereas A3G has such a
mechanism against HIV-1 by being efﬁciently incorporated into the
HIV-1 virion (Goila-Gaur and Strebel, 2008; Malim, 2009). Alterna-
tively, HPV16 may have a yet-to-be-deﬁned mechanism to suppress
A3 activity, as HIV-1 degrades A3s through the Vif-dependent path-
way (Goila-Gaur and Strebel, 2008; Malim, 2009).
This study did not precisely determine which viral DNA (episomal
or integrated) is targeted by hypermutation mechanism, because of
limited amount and quality of DNA from clinical samples. However, E2
3D-PCR analysis of RCA products revealed hypermutation of episomal
viral DNA (Fig. 2A and Fig. S3), suggesting that episomal DNA may be
one source of the hypermutated reads in #1300.
The observation of the hypermutation in vivo implies that A3s
may have contributed to viral evolution and that the evolutionary
analysis of HPV genomes should be performed taking mutation
pressure of A3s into account. Finally, recent cancer genomics
studies have suggested the involvement of A3-induced mutagen-
esis in the development of HPV-related cancers (Henderson et al.,
2014; Ohba et al., 2014). Further studies are therefore required to
determine the physiological signiﬁcance of A3-mediated hyper-
mutation in HPV-induced tumorigenesis.
Materials and methods
Clinical samples
Cervical swabs were collected from patients diagnosed with
CIN1 positive for HPV16 at the department of obstetrics and
gynecology, the Kanazawa University Hospital. The clinical diag-
nosis of CIN1 was made by histological analysis of punch biopsy
sample obtained under colposcopy. HPV typing was performed with
GENOSEARCH HPV 31 kit (Medical Biological Laboratories CO., LTD,
Nagoya, Japan) and Clinichip HPV kit (Sekisui Medical Co., Ltd.
Tokyo, Japan). Total DNA was isolated from cervical exfoliated cells
in the swabs using the QIAamp DNA Mini Kit (Qiagen). Total RNA
was isolated by TRIsure (Bioline) from a biopsy sample obtained
under colposcopy. All the clinical samples were collected after
obtaining written informed consent from the patients and were
used with the approval of the Ethics Committee of Kanazawa
University. Pooled total RNA from normal cervices was purchased
from Biochain Institute (R1234275-50 and R1234275-P). CaSki cells
were maintained in RPMI-1640 (Wako), supplemented with 10%
heat-inactivated fetal bovine serum and 1% penicillin/streptomycin.
RT-qPCR
Synthesis of cDNA and RT-qPCR were performed as previously
reported (Kitamura et al., 2013; Liang et al., 2013;Wang et al., 2014). In
brief, total RNA was treated with DNase I (Ambion) to digest genomic
DNA and was reverse-transcribed using PrimeScript reverse transcrip-
tase (Takara). The cDNA was ampliﬁed using speciﬁc primers for A3A,
A3B, A3C, A3DE, A3F, A3G, A3H, HPV16 E6, E7, and hypoxanthine
phosphoribosyltransferase 1 (HPRT1) (Herdman et al., 2006; Wang et
al., 2014). To calculate and compare the copy numbers of A3s between
samples, serially diluted plasmids containing each A3 and HPRT1were
used to prepare a standard curve. Copy number of HPRT1was used to
normalize cDNA amounts.
Detection of hypermutation in E2 by 3D-PCR
E2 3D-PCR was performed as described previously (Wang et al.,
2014). Brieﬂy, the initial PCR was performed using the primer pair
targeting nt3304-nt3617 in AF125673.1 as follows: 94 1C for 4 min;
followed by 35 cycles of 94 1C for 16 s, 55 1C for 20 s, and 68 1C for
50 s each and a ﬁnal elongation step at 65 1C for 10 min. Nested PCR
was performed on a MasterCycler Pro thermal cycler (Eppendorf)
using the primer pair targeting nt3376-nt3588, as follows: 87.0–
83.8 1C for 5 min; followed by 35 cycles of 87.0–83.8 1C for 45 s,
50 1C for 30 s and 65 1C for 38 s each and a ﬁnal elongation step at
65 1C for 10 min. The nested PCR ampliﬁed an E2 gene fragment
(nt3400-nt3564) in HPV DNA (GenBank accession number:
AF125673.1). The control plasmids were prepared as described
(Wang et al., 2014).
rTaq (Takara) was used for PCR in both 3D-PCR and the estima-
tion of mutation load because high-ﬁdelity DNA polymerase cannot
amplify uracilated DNA. To determine the frequency of mutations,
PCR fragments from 3D-PCR or standard (94 1C denaturation) PCR
were cloned into a T vector, and the indicated number of successful
recombinant clones were selected randomly and sequenced using an
ABI PRISM 3130 apparatus (Applied Biosystems). To identify muta-
tions, GenBank accession number AF125673.1 was used as a
reference sequence for HPV16.
Rolling circular ampliﬁcation (RCA)
We applied the protocol with the minor modiﬁcations described
in the previous studies, which reports the selective ampliﬁcation of
the covalently closed circular DNA of HBV (Chowdhury et al., 2013;
Kitamura et al., 2013), to the ampliﬁcation of HPV episomal DNA.
Total DNA from clinical samples was mixed with 14 HPV16-speciﬁc
primers (Table S1); denatured at 95 1C for 3 min; cooled down
sequentially at 50 1C for 15 s, 37 1C for 15 s and room temperature
and reacted with the phi29 DNA polymerase and buffers (New
England Biolabs) at 37 1C for 18 h, according to the manufacturer's
instruction. Of note, phi-29 DNA polymerase can amplify DNA that
contains uracil. Concatemeric products were digested with BamHI,
which cleaves the HPV16 genomic DNA only once. The 7.9-kb full-
genome products were gel extracted for further experiments.
NGS
Genomic DNA from the clinical sample #1300 as well as the
control plasmid was ampliﬁed using PfuTurbo Cx Hotstart DNA
polymerase (Agilent Technologies, Santa Clara, CA, USA) and the
primer pair targeting HPV16 genomic DNA nt7582-nt3944 in
AF125673.1. The 4267 bp amplicons were separated on a 1% agarose
gel and puriﬁed using the Wizard SV Gel and PCR Clean-Up System
(Promega, Madison,WI, USA). The puriﬁed DNAwas fragmented by an
acoustic solubilizer Covaris S2 (Covaris, Woburn, MA, USA), aiming the
peak target at 200 bp. The TruSeq DNA LT Sample Prep Kit (Illumina,
San Diego, CA, USA) was used to prepare DNA libraries. After adapter
ligation and puriﬁcation by the AMPure XP kit (Beckman Coulter,
Danvers, MA, USA), fragments were separated by electrophoresis on a
2% agarose gel, and size range corresponding to 350–450 bp (with the
expectation that Y shaped adapters run more slowly than double-
stranded DNA) of DNA marker was recovered and puriﬁed by the
MinElute Gel Extraction Kit (Qiagen). The library fragments with
adapters at both ends were enriched with 12 cycles of PCR. They
were multiplexed with adapters containing different index sequences
and simultaneously subjected to MiSeq using the MiSeq Reagent Kit
v3 (300 cycle 2). Adaptor ligated PhiX 174 DNA was added to the
library to verify processes in MiSeq.
Analysis of NGS data
The ﬂow diagram of the analysis is summarized in Fig. S1. The
human genome reference was obtained from: ftp://ftp-trace.ncbi.
nih.gov/1000genomes/ftp/technical/reference/human_g1k_v37.
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fasta.gz. The HPV16 DNA sequence (nt4001-nt4000, AF125673.1)
was used as a reference to identify HPV16 read. Because we found
a tiny amount of the HPV56 genome sequence derived from co-
infected HPV56 in the #1300 sample, we added the HPV56
sequence (EF177181.1) as a reference. The reference sequences of
human, HPV16, HPV56, and PhiX174 genome (NC_001422.1) were
pooled into a FASTA ﬁle and used as the reference to map the
Illumina sequences using BWA-MEM in paired-end mode specify-
ing both read1 and read2. The mapped data were sorted according
to the mapped target, and data that mapped to HPV16 were
deposited into the DRA database (DRA002959), so that any genetic
information from patients would not be revealed, but the HPV
data could be analyzed. As each sample may have different
background polymorphisms, the consensus sequences of the
amplicon were called by samtools from down-sampled data and
DDBJ (accession number; LC027223 for #1300, and LC027929 for
the plasmid control). After adapter trimming with cutadapt, reads
were mapped again to the consensus sequence for each sample to
identify mutations.
To identify mutations, whose difference from the consensus
were supported by sequence of both strands with high quality
value (QV), the bases with the sum of QV more than 60 (threshold)
were counted. To this end, a consensus sequence of read1 and
read2 was constructed for each pair of reads. Any bases over-
lapping the PCR primer were treated as quality value 0. Fragments
that exactly matched the end position of the 3D-PCR were
excluded from the analysis to avoid potential contamination. Any
fragments having more than a threshold of 3 Ns in the read
consensus were discarded. The fragments were sorted according
to the number of C-to-T or G-to-A mutations. The program used
for the analysis is available at https://github.com/tomoakin/Hyper
Mut. To exclude the possibility that any reported HPV strains or
HPV genotypes other than HPV16 and HPV56 are misrecognized as
hypermutated HPV16, reads with three or more C-to-T/G-to-A
mutations were individually subjected to BLASTN search with the
nt dataset as of June 2015.
Statistical analysis
Statistical analyses were performed using GraphPad Prism
(GraphPad Software). Two-tailed unpaired t-test and Pearson's
chi-squared test were used for RT-qPCR analysis and mutation
analyses, respectively. P valueso0.05 obtained between experi-
mental groups were considered statistically signiﬁcant. In all the
graphs in this study, the error bars indicate the standard error of the
mean from duplicated samples.
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